Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 143 Publications

21 Customer Reviews

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 NWXlVWpNS3m2b4TvfIlkKEG|c3H5 NHr5XGI2OCEQvF2= NHyxU3E1QCCq Ml\HSG1UVw>? NFHJWGlMcWyuczDj[YxteyCkeTDtc5JmKHSqYX6gPVkm M{TEfFExPDl7NkSz
OVCA 429 NWrNfopUTnWwY4Tpc44hSXO|YYm= M{X1R|MxOCCwTR?= M3[5V|Q5KGh? NYrhdolMTE2VTx?= M{jUeWRqe3K3cITzJIlvfGGldDDteYx1cWOnbHz1cIFzKHS3bX;yJJNxcGW{b3nkdy=> NGHqeZoyODl7OUe2Oi=>
RPMI8226 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPmOIFpOTByIH7N MVS0PEBp NIDsVI5FVVOR MnH2TWM2OD1|MDDuUS=> NEDvRpEyOTNyNkS4PS=>
Dox40 M4HWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH1NVAxKG6P MXy0PEBp MWDEUXNQ MmOxTWM2OD12MDDuUS=> NV[2UFJ{OTF|ME[0PFk>
MR20 NHXxZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GzcFExOCCwTR?= NUOzeoJCPDhiaB?= NIrNXYVFVVOR MofpTWM2OD1{MDDuUS=> NYX4fG1rOTF|ME[0PFk>
LR5 M{PxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzaNVAxKG6P M13BWVQ5KGh? MnK3SG1UVw>? MXvJR|UxRTJyIH7N MVuxNVMxPjR6OR?=
U266 Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfLZ2N7OTByIH7N MknFOFghcA>? Ml3RSG1UVw>? MmLITWM2OD1|IH7N MX:xNVMxPjR6OR?=
IM-9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnnNVAxKG6P MXK0PEBp NHPkSWxFVVOR MU\JR|UxRTZibl2= M2TTelEyOzB4NEi5
Hs Sultan MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0NVAxKG6P NITyRlY1QCCq Ml:1SG1UVw>? MXPJR|UxRTJyIH7N NEft[o8yOTNyNkS4PS=>
PAM-LY2 NFS2ZW1HfW6ldHnvckBCe3OjeR?= MYmxNFAhdk1? Mn\rNVIhcA>? M{jyXmROW09? MlfsTY5pcWKrdIOgUmYu|rqEIHHjeIl3[XSrb36= M1PzOVEyOzVyOUGz
PAM 212 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSxNFAhdk1? NEnxTpY4OiCq NFW3d5BFVVOR MnjnTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NXjJSmd5OTF|NUC5NVM>
PAM-LY2 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\qVVExOCCwTR?= MX23NkBp MlTSSG1UVw>? NEXJRlFKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NHPhTIMyOTN3MEmxNy=>
B4B8 MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf1NVAxKG6P M165blczKGh? M4G3OWROW09? Moe3TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MnjWNVE{PTB7MUO=
B7E3 MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEG2ZVEyODBibl2= NWPUXW83PzJiaB?= NWjsZ482TE2VTx?= MV;Jcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? Mn3jNVE{PTB7MUO=
UM-SCC-9 M{DWSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxNFAhdk1? NVTLUnJ7PzJiaB?= NHjjcolFVVOR MkXNTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NGPiV4IyOTN3MEmxNy=>
UM-SCC-11B NEfNTlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvMNVAxKG6P Mn7TO|IhcA>? MUfEUXNQ NHfv[5BKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= NHW3dnMyOTN3MEmxNy=>
H460 MW\GeY5kfGmxbjDBd5NigQ>? Mn\uNVAh|ryP MYCyOEBp NEC4TpRFVVOR Mn7aTY5lfWOnczDCZ4wuOiCyaH;zdIhwenmuYYTpc44h[W6mIHPs[YF3[WenIHPvdpJmdGG2ZXSge4l1cCCJMj3NJJBp[XOnIHHydoV{fA>? NYnPXJJbOTJ2OUKxNVc>
U266 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe1NFAhdmdxbXy= MYi0PEBp M2\tS2ROW09? MWTJcohq[mm2czDj[YxtKGe{b4f0bC=> NF7DcIYyOjZ|MU[xPS=>
ARH77 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TSV|UxOCCwZz;tcC=> MkLGOFghcA>? NYTuPZh2TE2VTx?= M4LrXWlvcGmkaYTzJINmdGxiZ4Lve5Rp MXWxNlY{OTZzOR?=
WAD-1 M2jwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO3PIR{PTByIH7nM41t Mn[3OFghcA>? NEnneY9FVVOR MmnZTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NYW2fZRUOTJ4M{G2NVk>
U266/LR7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Tu[VUxOCCwZz;tcC=> NXXhNINPPDhiaB?= NIHhRWZFVVOR MoP0TY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXzkS4tiOTJ4M{G2NVk>
U266/dox4 M{fWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH4OVAxKG6pL33s NWixSmRDPDhiaB?= Mkm2SG1UVw>? Ml7BTY5pcWKrdIOgZ4VtdCCpcn;3eIg> MlfjNVI3OzF4MUm=
RPMI8226/LR5 NUHPUm5[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTHOVAxKG6pL33s NIO3ZYc1QCCq M1TxcmROW09? MWPJcohq[mm2czDj[YxtKGe{b4f0bC=> M3zTR|EzPjNzNkG5
H460 NGHtNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWriVW1vOTBizszN NV36TWdLPzJiaB?= M3PscWROW09? NE\DcVZKSzVyPUGwNEBvVQ>? NHrnNJQyOjZ|MU[yNC=>
H358 NWm0boxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vnb|ExKM7:TR?= M3HybFczKGh? MX\EUXNQ NXr5RllJUUN3ME23NEBvVQ>? NYDadJJQOTJ4M{G2NlA>
H322 NU\H[VY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XHSVExKM7:TR?= MlzaO|IhcA>? M2HESWROW09? MknSTWM2OD14MkCgcm0> NWrZRWdOOTJ4M{G2NlA>
H460 NWjsTVc1TnWwY4Tpc44hSXO|YYm= MYmxNFAhdk1? NVfGXVRyOjRiaB?= MkPNSG1UVw>? NFvkN4hKdmS3Y3XzJGczNU1vcHjhd4Uh[XK{ZYP0JIFv\CC2dXL1cIlvKGG|c3XtZox6NWSrc3Hzd4Vu[my7 NVHWUGw2OTJ4M{G2NlA>
LNCap-Pro5 MoS2SpVv[3Srb36gRZN{[Xl? M1LkdFEh|ryP MmLtOEBp NW\CWJl1TE2VTx?= M1PkXnN1[WKrbHn6[ZMheDV| NVn2[Jd7OTR4MUK1N|I>
T29 MlXmRZBweHSxc3nzJGF{e2G7 NHP2R5Q2OCCwTR?= M1rublQ5KGhi M1\zVGROW09? MYLJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXewOJZpOTZ5N{ixO|k>
T29Kt1 NYi3R3JDSXCxcITvd4l{KEG|c3H5 NWXrSG9UPTBibl2= Ml\tOFghcCB? MVvEUXNQ Mo\3TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NXzVe2hLOTZ5N{ixO|k>
HCT116 MW\BdI9xfG:|aYOgRZN{[Xl? Ml;pOVAhdk1? M2fCclQ5KGhi MmS1SG1UVw>? NHfHblFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NX:yR25sOTZ5N{ixO|k>
HKe-3 MYjBdI9xfG:|aYOgRZN{[Xl? MnG2OVAhdk1? NGXwR4o1QCCqIB?= NFTDVldFVVOR NGDxSHFKdmS3Y3XzJINmdGxiYYDvdJRwe2m| M1;Jb|E3Pzd6MUe5
NB-1691 NULXb5JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTFNUDPxE1? M1jXcFczKGh? MXvJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV? M3nSVFE4Pjh7Nki0
CHLA-255 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxJO69VQ>? MU[3NkBp NWDFNnA1UW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl NInTc2gyPzZ6OU[4OC=>
SK-N-AS NWq3O4NET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\LR|Eh|ryP NFXQXoU4OiCq M1;3WmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= MmLwNVc3QDl4OES=
NB-1691 MWnGeY5kfGmxbjDBd5NigQ>? MY[xNEBvVQ>? NW[wN4lGOjRiaB?= NFjCSZpUcWewaX\pZ4FvfGy7IILl[JVk\XNiY3XscJMhcW5idHjlJGcxN0dzIIDoZZNm MXexO|Y5QTZ6NB?=
CHLA-255 Mnu4SpVv[3Srb36gRZN{[Xl? NGnNb|UyOCCwTR?= NX3w[W5xOjRiaB?= MnO4UY9l\XO2bImgdoVlfWOnczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2V? M3;RSFE4Pjh7Nki0
RPMI 8226 NYHIVmpOTnWwY4Tpc44hSXO|YYm= NYrEfZFWOjBibl2= NHHLU485KGh? NX20OYhoW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NXXUR3JXOTl2M{[wOVA>
MM.1S MWDGeY5kfGmxbjDBd5NigQ>? MUKyNEBvVQ>? M4f0OlghcA>? M1rtXHNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NHPUdngyQTR|NkC1NC=>
U266 MWnGeY5kfGmxbjDBd5NigQ>? MX:yNEBvVQ>? MWm4JIg> NGLmWJhUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MnXNNVk1OzZyNUC=
OPM1 NFnCUYlHfW6ldHnvckBCe3OjeR?= MUWyNEBvVQ>? MmjVPEBp MVHTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> M4DSe|E6PDN4MEWw
INA6 M4\2TmZ2dmO2aX;uJGF{e2G7 M{DP[FIxKG6P M{PC[VghcA>? M{fHdXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 M1rX[VE6PDN4MEWw
OPM2 M3XjcWZ2dmO2aX;uJGF{e2G7 M1rKdFIxKG6P NUHpPIRiQCCq MUfTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MnzNNVk1OzZyNUC=
RPMI 8226 NUHzV4JGTnWwY4Tpc44hSXO|YYm= NFnIRY0zOCCwTR?= NIW1[4U5KGh? MkTRTY5lfWOnczDEUmEhe3mwdHjld4l{ M1P5SFE6PDN4MEWw
BaF/3 NGnIdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPnUWNtOTByIH7N MYi0PEBp MlrxTWM2OD14LkKgcm0> M4joVlIxOzB3Nkmy
BaF/3-p210 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO2TY0yODBibl2= M1nqVlQ5KGh? M3jXUWlEPTB;ND63JI5O NEPoVIszODNyNU[5Ni=>
TCC-S MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDzNVAxKG6P MlrXOFghcA>? NEjUZZJKSzVyPUKuPEBvVQ>? NVThVGZ6OjB|MEW2PVI>
BaF/3 MnXoSpVv[3Srb36gRZN{[Xl? NXiwWJlQPiCwTR?= NWHyXZBZPDhiaB?= NWO4XFVJUW6mdXPld{BiKGe{ZXH0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 MlPkNlA{ODV4OUK=
BaF/3-p210 MWrGeY5kfGmxbjDBd5NigQ>? Mmj4OkBvVQ>? MnzGOFghcA>? MofVTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=> MXyyNFMxPTZ7Mh?=
BaF/3-p210 NH;zUnRHfW6ldHnvckBCe3OjeR?= NXGz[2N3PiCwTR?= NHLtXpYzPCCq M1nVPXJm\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBidmRidHjlJIFkfGm4aYT5JI9nKFKk M3G2clIxOzB3Nkmy
Raji NUHydWw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxJO69VQ>? M3zqSVI1KGh? MkP6VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M3HIRVIyOTdyOUi4
LCL-1 MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi0Uno1OSEQvF2= M{PKOlI1KGh? M3ixbnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUCyNVE4ODl6OB?=
LCL-2 NWHTXG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWexJO69VQ>? NHHZWWgzPCCq M3q2[HJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NX\hToo{OjFzN{C5PFg>
BJAB M3zXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrFV20yKM7:TR?= MYGyOEBp MWnS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MX2yNVE4ODl6OB?=
SNT-13 NF\3T|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLVOmwyKM7:TR?= MYeyOEBp M3\BcnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M4W5clIyOTdyOUi4
SNT-16 NH3iUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DlNVEh|ryP NVryWVR4OjRiaB?= M4TmTXJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MUSyNVE4ODl6OB?=
Jurkat NVf3Nod2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS5NUDPxE1? MWiyOEBp NIWyVHNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NVXaZXhiOjFzN{C5PFg>
KAI-3 NGLlOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqyNUDPxE1? M4XCWlI1KGh? NHHSUFJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= M2nVUlIyOTdyOUi4
SNK-6 NWjWVYg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLPWWQyKM7:TR?= MUWyOEBp NEHROG9T\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MV[yNVE4ODl6OB?=
KHYG-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixJO69VQ>? Mkf0NlQhcA>? MmrmVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MX:yNVE4ODl6OB?=
SNT-16 MYPBdI9xfG:|aYOgRZN{[Xl? NWe3cY16OSEQvF2= MnW4OkBp M1zH[Glv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXSyNVE4ODl6OB?=
Jurkat MlflRZBweHSxc3nzJGF{e2G7 MXWxJO69VQ>? NYLyPWlxPiCq Mn3QTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NH;sSJYzOTF5MEm4PC=>
KAI-3 NHTqeZRCeG:ydH;zbZMhSXO|YYm= NITBc2YyKM7:TR?= NYnicZBKPiCq MWDJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NEDJbWIzOTF5MEm4PC=>
KHYG-1 NFvMT|BCeG:ydH;zbZMhSXO|YYm= M2\4XVEh|ryP M{\idVYhcA>? MlH2TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NUHFVndXOjFzN{C5PFg>
SNT-13 MWDBcpRqfmm{YXygRZN{[Xl? MnP5NUDPxE1? MWqyOEBp NEWzTXlKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NXT6PFRDOjFzN{C5PFg>
SNT-16 M{TNNWFvfGm4aYLhcEBCe3OjeR?= M2TOcFEh|ryP NYTR[4M2OjRiaB?= MX\JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NXfnbY1nOjFzN{C5PFg>
KAI-3 MU\BcpRqfmm{YXygRZN{[Xl? NFjwS5UyKM7:TR?= NWHqZ2RzOjRiaB?= MYfJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M3nqbVIyOTdyOUi4
SNK-6 MW\BcpRqfmm{YXygRZN{[Xl? NX[xT5BiOSEQvF2= MV:yOEBp NWnIbJRuUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY NGDKV4kzOTF5MEm4PC=>
RAW 264.7 M4OwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojjNVAxKG6P NYrXZ29{PDhiaB?= M2eye3Jm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= NWXKS3RSOjJ2MkexOVQ>
A375 MoTJRZBweHSxc3nzJGF{e2G7 NXflOlQ6OTBibl2= MViyOEBp Ml\KTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUKyN|A4QTB6Mx?=
BLM NIO1[XZCeG:ydH;zbZMhSXO|YYm= NGHHWJUyOCCwTR?= MoTDNlQhcA>? NGS2cYJKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NVHGWY51OjNyN{mwPFM>
A375 NES4TWtCfXSxcHjh[5khSXO|YYm= M2LSR|ExKG6P NHHteoMyOiCq NVjlTIFVUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MoPzNlMxPzlyOEO=
BLM MYTBeZRweGijZ4mgRZN{[Xl? Mln0NVAhdk1? M1PzV|EzKGh? MXXJcoR2[2W|IH\vdo1ifGmxbjDv[kBifXSxcHjh[49{d22ncx?= NUfZNnA2OjNyN{mwPFM>
H1299 MXrBdI9xfG:|aYOgRZN{[Xl? NHfW[pM5OCCwTR?= MUSyOEBp M3;QNGROW09? NFzKbpdU\W6|aYTpfoV{KE6VQ1zDJINmdGy|IITvJG1USy2mZYLpeoVlKGmFOT3pcoR2[2WmIHHwc5B1d3Orcx?= NFz5OFkzPTN{M{[5Ny=>
Hut-78 NH7KOI5HfW6ldHnvckBCe3OjeR?= M1HQUVExOCCwTR?= MV6yOEBp Mom4SG1UVw>? NWjVZoRwTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMDDlfJBz\XO|aX;u NILwenQzPTZ6MUOzOS=>
H9 NFnqTGtHfW6ldHnvckBCe3OjeR?= MYWxNFAhdk1? MkDiNlQhcA>? NXrvN3BtTE2VTx?= NYDaTlcxTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u M2TVe|I2PjhzM{O1
HH MX7GeY5kfGmxbjDBd5NigQ>? MnrNNVAxKG6P NHHHRXQzPCCq MULEUXNQ M3rQbIRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?= Mn;CNlU3QDF|M{W=
Hut-78 NGXtS2NOcWe{YYTpc44hSXO|YYm= MmnLNVAxKG6P MWWyOEBp MnzSSG1UVw>? NH;HSW9T\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUCl MX6yOVY5OTN|NR?=
HH M4rKdm1q\3KjdHnvckBCe3OjeR?= M4PzS|ExOCCwTR?= NYjQOHVkOjRiaB?= MonqSG1UVw>? Mn3SVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?= MXuyOVY5OTN|NR?=
U937 M2X1N2Z2dmO2aX;uJGF{e2G7 MnHXNVAxKG6P M1;adVYhcA>? NHu0V5BKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| Mn\BNlU4QTF2N{e=
human PBMC MVrGeY5kfGmxbjDBd5NigQ>? M3rMflExOCCwTR?= M2DmflI1KGh? NVHhNFhXUW6mdXPld{BKVC16IILlcIVie2V? NVz4d|NUOjV5OUG0O|c>
ES6 NFjUUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:0TWM2OD1yLkCwNlEhdk1? NUDvUJJiW0GQR1XS
SK-UT-1 NFjHSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMU[zJI5O MVHTRW5ITVJ?
SH-4 NFzabYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDtNFRKSzVyPUCuNVc{KG6P M{m4eHNCVkeHUh?=
TE-9 NWLuW257T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXvTWM2OD1yLkG4NkBvVQ>? Ml62V2FPT0WU
A253 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3rSnVoUUN3ME2wMlIxQCCwTR?= MnzrV2FPT0WU
no-10 NUPifVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULvWGRYUUN3ME2wMlIyKG6P NE\O[5RUSU6JRWK=
MMAC-SF NUfTT4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMkG2JI5O MlnyV2FPT0WU
A101D MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\zTWM2OD1yLkKyOUBvVQ>? NWjMOGM6W0GQR1XS
NTERA-S-cl-D1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:4WGlEPTB;MD6yOFMhdk1? M3PaUHNCVkeHUh?=
8-MG-BA M3nGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HxSGlEPTB;MD6yOUBvVQ>? MX7TRW5ITVJ?
KNS-42 NUnHfJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXvfI5KSzVyPUCuNlU5KG6P MWTTRW5ITVJ?
LXF-289 M1\jSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPqSWZKSzVyPUCuNlY6KG6P MX7TRW5ITVJ?
OVCAR-4 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHsOlhKSzVyPUCuNlg6KG6P MXPTRW5ITVJ?
LOUCY M{PLTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fzWWlEPTB;MD6yPVMhdk1? NIrGSoJUSU6JRWK=
BB65-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m2WGlEPTB;MD6zNFQhdk1? M3fkOHNCVkeHUh?=
D-542MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLDUYZKSzVyPUCuN|I6KG6P NXjZWYViW0GQR1XS
ONS-76 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjkdWFKSzVyPUCuN|Mhdk1? M2PoU3NCVkeHUh?=
BB30-HNC M13QWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfObJNKSzVyPUCuN|M2KG6P MYfTRW5ITVJ?
KS-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwM{Sgcm0> NEK3SYJUSU6JRWK=
A388 NW[0NJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXHTWM2OD1yLkO1OkBvVQ>? NEHOSHRUSU6JRWK=
ES8 M2\Nbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfOcJFMUUN3ME2wMlQhdk1? NIPHfHpUSU6JRWK=
MZ2-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[4TWM2OD1yLkSwO{BvVQ>? NVzVcXdbW0GQR1XS
HCC2998 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M322VmlEPTB;MD60NVIhdk1? NGn4XndUSU6JRWK=
D-247MG MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHrTWM2OD1yLkSxN{BvVQ>? MX\TRW5ITVJ?
ACN MnTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT1doFPUUN3ME2wMlQyPyCwTR?= MX\TRW5ITVJ?
LB2518-MEL NHfRSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwNEK1JI5O MWXTRW5ITVJ?
ES1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XSeWlEPTB;MD60N{BvVQ>? NWm3NYVHW0GQR1XS
HCE-T NIfrSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmxR3M3UUN3ME2wMlQ{QSCwTR?= MWDTRW5ITVJ?
OS-RC-2 M4m5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37wXWlEPTB;MD60OEBvVQ>? MVPTRW5ITVJ?
MFH-ino NES2XVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO4TWM2OD1yLkS0N{BvVQ>? Mmr5V2FPT0WU
OCUB-M NHXVXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXkXJVKSzVyPUCuOFQ4KG6P M4HZT3NCVkeHUh?=
CP66-MEL NFz6UlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjETWM2OD1yLkS3N{BvVQ>? MWPTRW5ITVJ?
LB771-HNC NUDISIhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPafoVnUUN3ME2wMlQ4PCCwTR?= NX7JO292W0GQR1XS
DSH1 MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jidWlEPTB;MD60PEBvVQ>? MWrTRW5ITVJ?
HUTU-80 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC2TWM2OD1yLkWzN{BvVQ>? NYKwSWlIW0GQR1XS
CESS M{PFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTtUWRKSzVyPUCuOVM5KG6P M4K4OnNCVkeHUh?=
NCI-H747 M4HUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXITWM2OD1yLkWzPUBvVQ>? NXGxZm0xW0GQR1XS
HT-144 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwNUe2JI5O NIX0[JVUSU6JRWK=
COLO-829 NXrXdFl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzpTWM2OD1yLk[xOEBvVQ>? MoriV2FPT0WU
A4-Fuk M3qzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfWTWM2OD1yLk[yN{BvVQ>? MlLhV2FPT0WU
GI-ME-N MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jHeGlEPTB;MD62N|Qhdk1? Mo\FV2FPT0WU
LB831-BLC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi1e|FKSzVyPUCuOlQyKG6P NVrvRWFKW0GQR1XS
HOP-62 MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D6SWlEPTB;MD62OFchdk1? M3z5PXNCVkeHUh?=
BB49-HNC M4W3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzUbXllUUN3ME2wMlY2OiCwTR?= NH\wTXhUSU6JRWK=
D-336MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHTTWM2OD1yLk[1O{BvVQ>? M{O2SnNCVkeHUh?=
TK10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK3[HVKSzVyPUCuOlc6KG6P MUPTRW5ITVJ?
Ramos-2G6-4C10 M3:wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHZemxKSzVyPUCuOlk{KG6P MVTTRW5ITVJ?
LB373-MEL-D M3[wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwNzDuUS=> M3TyU3NCVkeHUh?=
SF126 NG\tR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3uTnU3UUN3ME2wMlcxOSCwTR?= M3XkcXNCVkeHUh?=
UACC-257 NG\1XYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPHZ2JKUUN3ME2wMlcyKG6P M33oV3NCVkeHUh?=
KINGS-1 MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPBbGJKSzVyPUCuO|IzKG6P MXvTRW5ITVJ?
LS-513 NVLaSWY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTkTWM2OD1yLkezPUBvVQ>? NVmzd4JEW0GQR1XS
GI-1 NYSye4RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPJVohKSzVyPUCuO|Y1KG6P NXn6cWZZW0GQR1XS
ES7 NIHSblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rRVGlEPTB;MD63OlYhdk1? NFnDSZlUSU6JRWK=
LB2241-RCC M{PWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOxPJo2UUN3ME2wMlgxPCCwTR?= MUHTRW5ITVJ?
D-263MG NXLKflhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LXVGlEPTB;MD64NFchdk1? NYPGcG5oW0GQR1XS
SW684 NIPrNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr6S4E2UUN3ME2wMlgzOSCwTR?= M1HnVHNCVkeHUh?=
ML-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnwWWpoUUN3ME2wMlgzOSCwTR?= MWLTRW5ITVJ?
SK-LMS-1 NIfzO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nEcmlEPTB;MD64OVQhdk1? M4POXHNCVkeHUh?=
TE-5 NXnTWmVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jaTWlEPTB;MD64OlUhdk1? NVHRcVVMW0GQR1XS
QIMR-WIL M3TiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPoTWM2OD1yLki4PUBvVQ>? Mn;sV2FPT0WU
NCI-H1355 M4K5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPITWM2OD1yLki5OUBvVQ>? M2j4VXNCVkeHUh?=
SNB75 NEX6[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWyTWM2OD1yLkmxNkBvVQ>? NFXvdGpUSU6JRWK=
RXF393 NYKwPGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwOUG0JI5O MlXwV2FPT0WU
IST-MEL1 NGHIUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3lRmVKSzVyPUCuPVE4KG6P M1\uN3NCVkeHUh?=
SF268 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M136WWlEPTB;MD65NlMhdk1? NGn1foRUSU6JRWK=
KALS-1 M12xfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwOUK1JI5O MYfTRW5ITVJ?
HC-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu3[HlYUUN3ME2wMlk4PSCwTR?= NH\a[ZRUSU6JRWK=
SW872 M4LL[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX4TWM2OD1yLkm5OkBvVQ>? NFjNdIlUSU6JRWK=
PSN1 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\5VGlEPTB;MT6wNUBvVQ>? NX3KUFNKW0GQR1XS
TE-1 NInVfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwMEOgcm0> M3LiNnNCVkeHUh?=
TE-10 NXTLWoNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMEOgcm0> NELvRZFUSU6JRWK=
RKO NVv1fmhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\JTWlEPTB;MT6wOkBvVQ>? NUfVSIZDW0GQR1XS
LC-2-ad M3PG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFwMEigcm0> NG[yRnhUSU6JRWK=
SK-MM-2 NUfKZ5FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHtZnl[UUN3ME2xMlA6KG6P NUOxW3NGW0GQR1XS
VA-ES-BJ NIH0PGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTFwMEmgcm0> M4W0XHNCVkeHUh?=
MZ7-mel NIjJU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwMEmgcm0> NEDqRYVUSU6JRWK=
D-392MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIf6SXpKSzVyPUGuNUBvVQ>? NFTmPHNUSU6JRWK=
CCRF-CEM NG\0XGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfFTWM2OD1zLkGzJI5O NVLQTJlKW0GQR1XS
EM-2 M3rwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL1TWM2OD1zLkG2JI5O NUezUXBRW0GQR1XS
HAL-01 NUnIb29WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rT[WlEPTB;MT6xPEBvVQ>? NFT1TWhUSU6JRWK=
TE-8 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPKWoFKSzVyPUGuNVkhdk1? MnLCV2FPT0WU
NCI-H1882 NFHBZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TVcmlEPTB;MT6yJI5O M3;iTHNCVkeHUh?=
Daudi MnzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP1TWM2OD1zLkKyJI5O MUDTRW5ITVJ?
BL-41 M13CZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\KXopuUUN3ME2xMlI2KG6P NGraNYdUSU6JRWK=
SR NUTJXFNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\mTWM2OD1zLkK1JI5O NEjnbYVUSU6JRWK=
KM12 NV7TeFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHP[3NKSzVyPUGuNlchdk1? MojZV2FPT0WU
K5 NWLtfXdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjpR2NuUUN3ME2xMlI5KG6P MYPTRW5ITVJ?
A3-KAW M3;1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFwMkigcm0> NWPCdWFEW0GQR1XS
CMK NUGxT5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIqyOJVKSzVyPUGuNlkhdk1? NFTh[IRUSU6JRWK=
Calu-6 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\pbJluUUN3ME2xMlI6KG6P NX3ET2RJW0GQR1XS
IST-SL2 NELhS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD1zLkOxJI5O MWrTRW5ITVJ?
OPM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoflTWM2OD1zLkOzJI5O NXL0N|UxW0GQR1XS
DU-4475 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfVTWM2OD1zLkO2JI5O MYnTRW5ITVJ?
ECC12 NV3ocWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwM{egcm0> NFnYcoVUSU6JRWK=
L-540 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFP6fZlKSzVyPUGuN|chdk1? MnzCV2FPT0WU
CAS-1 NWToeWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvtTXdJUUN3ME2xMlM4KG6P NFewcGRUSU6JRWK=
PF-382 NYjJTXN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;WTmk1UUN3ME2xMlQ4KG6P NGT4N3VUSU6JRWK=
LS-411N MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFwNUOgcm0> M4\vV3NCVkeHUh?=
NCI-H69 NH;yfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn72TWM2OD1zLkW0JI5O M1f0XnNCVkeHUh?=
NB12 MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDVbYxKSzVyPUGuOVYhdk1? NFPzenRUSU6JRWK=
HEL M3TENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnLdVdKSzVyPUGuOlEhdk1? MUTTRW5ITVJ?
GCIY NUjiNnpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfuRVU4UUN3ME2xMlYzKG6P NH\vZ|hUSU6JRWK=
EHEB Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzHZ4lzUUN3ME2xMlY4KG6P M{\QRnNCVkeHUh?=
TGBC1TKB MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwN{Ggcm0> MmrrV2FPT0WU
KURAMOCHI NHXhfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj3Olg6UUN3ME2xMlczKG6P M{X5WnNCVkeHUh?=
U-266 NF3Ld5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW0fGs4UUN3ME2xMlc3KG6P MlfzV2FPT0WU
LC4-1 NIO2XpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwN{mgcm0> NXPRTGNpW0GQR1XS
NCI-H2126 NHvYVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP2bYJKSzVyPUGuPEBvVQ>? MoPVV2FPT0WU
NCI-H1092 NGezbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jk[WlEPTB;MT64JI5O NYfrfms2W0GQR1XS
GB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrKTWM2OD1zLkixJI5O NFLRWJhUSU6JRWK=
MV-4-11 NXi2fo5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;vb2RJUUN3ME2xMlgzKG6P NHniSFJUSU6JRWK=
Becker Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\qb5B2UUN3ME2xMlg{KG6P NFTWUGVUSU6JRWK=
MPP-89 MoPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnFSnc6UUN3ME2xMlg6KG6P Mne4V2FPT0WU
BE-13 NYr2Tnh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPrTWM2OD1zLkmzJI5O NVfsb216W0GQR1XS
697 NFTZZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTrW2tKSzVyPUGuPVkhdk1? M{DUR3NCVkeHUh?=
NKM-1 NIG4O2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGD0blNKSzVyPUKgcm0> MkPsV2FPT0WU
NB13 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1{IH7N NFO3XJJUSU6JRWK=
LS-123 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHMTWM2OD1{LkCyJI5O NH\hfpdUSU6JRWK=
NB17 NXH6S29jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fCSmlEPTB;Mj6wOEBvVQ>? MYjTRW5ITVJ?
LAN-6 NHOzNVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTJwMEWgcm0> Ml3GV2FPT0WU
EW-24 NUXJT|BJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TSWmlEPTB;Mj6wPEBvVQ>? M4XEOXNCVkeHUh?=
NOS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJwMUGgcm0> MWHTRW5ITVJ?
BL-70 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvRbYtKSzVyPUKuNVIhdk1? MlXpV2FPT0WU
GT3TKB M3nDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJwMUKgcm0> NW\sb2VbW0GQR1XS
HH MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\vTWM2OD1{LkGzJI5O NGrFNFdUSU6JRWK=
KE-37 NX;RfGhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHRZXZKSzVyPUKuNVMhdk1? NH\0eIxUSU6JRWK=
MOLT-4 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Tzd2lEPTB;Mj6xN{BvVQ>? M{HORXNCVkeHUh?=
EKVX M4DBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJwMUSgcm0> NIPQNGZUSU6JRWK=
KGN Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\ubmlEPTB;Mj6xOUBvVQ>? MmDlV2FPT0WU
ES4 NIX3TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;yTJNKSzVyPUKuNVYhdk1? NYjkTXVJW0GQR1XS
SJSA-1 NHrrWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwMkGgcm0> MmjxV2FPT0WU
KMOE-2 NF6yTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jFd2lEPTB;Mj6yN{BvVQ>? M4n0OnNCVkeHUh?=
NB5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi4VXhKSzVyPUKuNlchdk1? NGnnPGNUSU6JRWK=
BC-1 NXX1R2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr2WopzUUN3ME2yMlMyKG6P M3jMdXNCVkeHUh?=
NB10 NWfGN49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfVTWM2OD1{LkOyJI5O NWXROI1GW0GQR1XS
RPMI-8226 Mn24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwM{Wgcm0> NYH4WlZ7W0GQR1XS
SCC-3 NFvYN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:4flFKSzVyPUKuN|chdk1? MkPkV2FPT0WU
ARH-77 M{m3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTmWmhKSzVyPUKuN|ghdk1? M{jhVnNCVkeHUh?=
NCI-H748 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJwM{mgcm0> Mn7vV2FPT0WU
KU812 NYLsZYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q1NGlEPTB;Mj60NkBvVQ>? MlTZV2FPT0WU
NCI-H64 Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvHTWM2OD1{LkS0JI5O NHfseFZUSU6JRWK=
NB69 NGXyeG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwNE[gcm0> MYnTRW5ITVJ?
KNS-81-FD MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\HZ4pKSzVyPUKuOFghdk1? NFqwSHhUSU6JRWK=
LB1047-RCC NViwdGNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwNUegcm0> NVHjd2FPW0GQR1XS
EB-3 NFLufpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ETWM2OD1{Lk[2JI5O NVfxR2ZFW0GQR1XS
Mo-T NXv0blJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJwN{Sgcm0> NIfFZ3ZUSU6JRWK=
EW-16 NV;qZZFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4P5fWlEPTB;Mj63OUBvVQ>? MV3TRW5ITVJ?
CTV-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwODDuUS=> NXz0PVFoW0GQR1XS
ETK-1 NYKzRoZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLoWGxKSzVyPUKuPFQhdk1? MoXKV2FPT0WU
C2BBe1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPLcW9KSzVyPUKuPFkhdk1? MmjVV2FPT0WU
MOLT-16 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DBUmlEPTB;Mj64PUBvVQ>? MYHTRW5ITVJ?
SW954 MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[0TWM2OD1{Lkmgcm0> M4OxXnNCVkeHUh?=
HT NWr5Umw3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jmTWlEPTB;Mz6wNkBvVQ>? NGXQXmlUSU6JRWK=
KARPAS-299 MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn72TWM2OD1|LkC2JI5O NInZflBUSU6JRWK=
MONO-MAC-6 NEHoRotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjj[Wc{UUN3ME2zMlEhdk1? M3SwdHNCVkeHUh?=
CGTH-W-1 NWjCcJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELXbFRKSzVyPUOuNUBvVQ>? MUnTRW5ITVJ?
SK-PN-DW M{ToSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDTUHJiUUN3ME2zMlE1KG6P MmfCV2FPT0WU
CW-2 NWfUXJRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPqfGZ[UUN3ME2zMlIyKG6P M4THd3NCVkeHUh?=
SK-N-DZ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjMTWM2OD1|LkK2JI5O M4nYSXNCVkeHUh?=
NEC8 NYi3WZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\JbmlEPTB;Mz6zOUBvVQ>? Mn3ZV2FPT0WU
LB996-RCC NVna[5BST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV76cXBuUUN3ME2zMlQhdk1? NIrLNm1USU6JRWK=
DB NYeyNVA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTNwNEGgcm0> M3zxOXNCVkeHUh?=
TE-15 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHwTWM2OD1|LkSzJI5O NXnk[mVIW0GQR1XS
COR-L88 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7jVXVnUUN3ME2zMlQ4KG6P MU\TRW5ITVJ?
LAMA-84 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHONHdKSzVyPUOuOFkhdk1? MoLaV2FPT0WU
MEG-01 NUXrSJI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f2WWlEPTB;Mz60PUBvVQ>? M2DOT3NCVkeHUh?=
LOXIMVI NUO2dYJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTNwNTDuUS=> NV;wXZZQW0GQR1XS
RPMI-8402 NWrwSmdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;Kc|ZKSzVyPUOuOUBvVQ>? MmqzV2FPT0WU
KARPAS-45 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPS[pFkUUN3ME2zMlU1KG6P MlfSV2FPT0WU
HCC1187 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETZfG9KSzVyPUOuOVQhdk1? Mn3HV2FPT0WU
MZ1-PC NWPNdHpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTNwNUSgcm0> M1fBb3NCVkeHUh?=
no-11 M4TVeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvETmRVUUN3ME2zMlU2KG6P NGHjbYRUSU6JRWK=
EVSA-T Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS3cZNKSzVyPUOuOkBvVQ>? MWDTRW5ITVJ?
DJM-1 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHHToxPUUN3ME2zMlY{KG6P MVvTRW5ITVJ?
COLO-684 M1vEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L6NGlEPTB;Mz62OkBvVQ>? M1HuZnNCVkeHUh?=
NMC-G1 M325VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LPdWlEPTB;Mz62PEBvVQ>? NHrUT4hUSU6JRWK=
LC-1F NI\mdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\jTWM2OD1|Lke0JI5O NEXqW4RUSU6JRWK=
RL95-2 MmT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP3TWM2OD1|Lke5JI5O MXfTRW5ITVJ?
COLO-320-HSR MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNwOUKgcm0> NUT6fmp5W0GQR1XS
RCC10RGB M3q5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfUWm5KSzVyPUOuPVMhdk1? M3nmVXNCVkeHUh?=
HD-MY-Z M1[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfmTWM2OD1|LkmzJI5O MXjTRW5ITVJ?
NCI-H2141 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXYTWM2OD12LkC1JI5O NILD[YNUSU6JRWK=
K-562 NEXTbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnYT|BHUUN3ME20MlEzKG6P MmLLV2FPT0WU
NCI-H1648 MmC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD12LkGzJI5O Mn3hV2FPT0WU
OMC-1 NHizTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTDXJRQUUN3ME20MlE5KG6P MWDTRW5ITVJ?
LB647-SCLC NGTNVpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnGTIh6UUN3ME20MlIzKG6P MX\TRW5ITVJ?
TE-12 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nHT2lEPTB;ND6yOUBvVQ>? NHf2O4JUSU6JRWK=
NOMO-1 NHXZOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO2UVhiUUN3ME20MlM{KG6P M1PZfXNCVkeHUh?=
Raji MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi3UndKSzVyPUSuOFYhdk1? NV:3N5BqW0GQR1XS
NALM-6 NXKyb2Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYOxRlMxUUN3ME20MlQ6KG6P MYrTRW5ITVJ?
HL-60 MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHWfHhKSzVyPUSuOlchdk1? NYLERm5CW0GQR1XS
IST-SL1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jHOGlEPTB;ND62PEBvVQ>? M1LVfnNCVkeHUh?=
MHH-PREB-1 NVfSUJdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIruUppKSzVyPUSuPFYhdk1? Mk\EV2FPT0WU
MHH-NB-11 NXvJOZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRwOUGgcm0> MVTTRW5ITVJ?
JiyoyeP-2003 NYHieo9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn1ZWF3UUN3ME21JI5O NUK1O|N4W0GQR1XS
SBC-1 M2ewbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHDUooyUUN3ME21MlAyKG6P MWTTRW5ITVJ?
CHP-126 NGDBcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIm0XY1KSzVyPUWuNFYhdk1? M3H3XnNCVkeHUh?=
LU-139 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX4TWM2OD13LkGzJI5O M4PjbnNCVkeHUh?=
NCI-SNU-5 M33od2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT2Uo5KSzVyPUWuNVchdk1? MWnTRW5ITVJ?
SW962 NXvOTnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HRXWlEPTB;NT6yNUBvVQ>? MX3TRW5ITVJ?
EW-1 NGLGVpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrrTWM2OD13LkOxJI5O NHvCZm5USU6JRWK=
NCI-H1417 M4\hfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfxTWM2OD13LkWxJI5O M1TwUnNCVkeHUh?=
LU-65 NV3KT25IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyxTWM2OD13Lki0JI5O M1jMe3NCVkeHUh?=
D-502MG NEjXTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTZwM{egcm0> MnvFV2FPT0WU
BC-3 NYXLZYkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rpXWlEPTB;Nj62NUBvVQ>? Ml;PV2FPT0WU
GDM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXJOZVlUUN3ME22Mlc4KG6P NXrpSINbW0GQR1XS
NCI-H2196 M4faS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPXZVNEUUN3ME22Mlghdk1? M2fIfnNCVkeHUh?=
NB1 NI\YNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjqXGR{UUN3ME22Mlg5KG6P NHfsV25USU6JRWK=
NCI-H345 NXm0fpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3D[nhKSzVyPUeuNkBvVQ>? MWHTRW5ITVJ?
SU-DHL-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTdwMkSgcm0> NV;MWG1XW0GQR1XS
JVM-2 NHvk[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2THemlEPTB;Nz6yPEBvVQ>? MlTWV2FPT0WU
LU-134-A MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzKUmNKSzVyPUeuN|khdk1? MWLTRW5ITVJ?
NCI-H1694 Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTdwNUigcm0> NEHybIFUSU6JRWK=
NCI-SNU-16 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTdwNkWgcm0> M4jiNnNCVkeHUh?=
L-363 NVPuO5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfOTWM2OD15Lkegcm0> MlzEV2FPT0WU
KG-1 M1jkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PCdGlEPTB;Nz65OEBvVQ>? Ml;UV2FPT0WU
MN-60 NF;4bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL6SXFKSzVyPUiuNVQhdk1? NEnNbWlUSU6JRWK=
NB6 Ml\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki0TWM2OD16LkS4JI5O NUTCeGxkW0GQR1XS
MLMA NUnKNINET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M321WGlEPTB;OD64OUBvVQ>? M2XaNHNCVkeHUh?=
ATN-1 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\VTWM2OD16Lki5JI5O NXHEUWc6W0GQR1XS
SK-NEP-1 NVviTZBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILDXIVKSzVyPUmuNFEhdk1? NFy3cnNUSU6JRWK=
DMS-114 MlO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\je45KSzVyPUmuOlIhdk1? M2nGUnNCVkeHUh?=
CTB-1 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnxUWZEUUN3ME25MlY4KG6P MYXTRW5ITVJ?
NCI-H2081 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL3TWM2OD1zMD6wPUBvVQ>? M3LwUnNCVkeHUh?=
ES5 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HWW2lEPTB;MUCuN|ghdk1? M2Xw[HNCVkeHUh?=
HCC1599 M1z1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LV[mlEPTB;MUGuPVEhdk1? MUPTRW5ITVJ?
NCI-H23 NUDGN4s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPkOI1LUUN3ME2xNk4yOiCwTR?= NXvX[HJEW0GQR1XS
NCI-H1581 NHvuU2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF{LkK4JI5O NFzOZlVUSU6JRWK=
JVM-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrCUm5ZUUN3ME2xNk46QSCwTR?= MoL2V2FPT0WU
NCI-SNU-1 NFrIZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojITWM2OD1zMz6xPUBvVQ>? NFvmU29USU6JRWK=
NB7 M3PzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXlPXBFUUN3ME2xOU46OiCwTR?= MV3TRW5ITVJ?
JAR MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOw[HVKSzVyPUG2MlE{KG6P MU\TRW5ITVJ?
TGW MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3KN49TUUN3ME2xOk41QCCwTR?= NFHRXVBUSU6JRWK=
U-87-MG NIDVfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[5SmlEPTB;MU[uO|Yhdk1? MXvTRW5ITVJ?
NCI-H1436 M3X3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\pTWM2OD1zNz6wNUBvVQ>? NIK3XpNUSU6JRWK=
GOTO MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrUT|dxUUN3ME2xO{4xPiCwTR?= MYHTRW5ITVJ?
COLO-800 NFH1XIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z1fGlEPTB;MUeuOlQhdk1? MljxV2FPT0WU
MFM-223 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDlTHFKSzVyPUG3MlkyKG6P MXjTRW5ITVJ?
EW-18 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTF5Lkm2JI5O Ml;EV2FPT0WU
NB14 M3j4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF5Lkm4JI5O MYfTRW5ITVJ?
EB2 NXLQcIhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljvTWM2OD1zOD6wPEBvVQ>? NHXaSoRUSU6JRWK=
EoL-1- NYj6Z5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF6LkOxJI5O NGHMPWNUSU6JRWK=
NCCIT NFHLRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLGe2VvUUN3ME2xPE4{PiCwTR?= Mn3SV2FPT0WU
DG-75 NVz2VI02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHOTHBKSzVyPUG4MlYyKG6P MX\TRW5ITVJ?
HCC2218 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Xy[GlEPTB;MUmuOUBvVQ>? NHviWI5USU6JRWK=
TE-6 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfkbnhKSzVyPUKwMlA5KG6P M4O3VnNCVkeHUh?=
SF539 NFXJNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfPSYFvUUN3ME2yNE43PyCwTR?= NWq1SotuW0GQR1XS
NCI-H446 NW\YRXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvNGlKSzVyPUKxMlE5KG6P NFO0XG9USU6JRWK=
IST-MES1 M2LYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17lNWlEPTB;MkKuO|chdk1? M1S1N3NCVkeHUh?=
NCI-H82 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfwTWM2OD1{Mz6wNkBvVQ>? NVrYVIhJW0GQR1XS
HCC2157 MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj0e|dKSzVyPUKzMlE{KG6P NIOxZWRUSU6JRWK=
EW-12 NEDFdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnWTWM2OD1{Mz6xO{BvVQ>? NV;BPZpYW0GQR1XS
SIMA NEPPfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\oe2lEPTB;MkOuN|ghdk1? M3zNTHNCVkeHUh?=
DOHH-2 NEXCUYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ|LkS1JI5O MVfTRW5ITVJ?
IM-9 NUS1d|V5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHjTWM2OD1{Mz61OEBvVQ>? MVLTRW5ITVJ?
EC-GI-10 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf3TWM2OD1{ND6yN{BvVQ>? M1zBUHNCVkeHUh?=
HDLM-2 MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ2LkW0JI5O NGPvTW5USU6JRWK=
LS-1034 NGLSN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LMbGlEPTB;MkWuO|Uhdk1? MnHhV2FPT0WU
REH MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTJ4LkSxJI5O MWXTRW5ITVJ?
LU-165 NUHiXHQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTJ4LkeyJI5O NFntco5USU6JRWK=
NH-12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfnSWlKSzVyPUK3MlY4KG6P NVHp[nE3W0GQR1XS
WSU-NHL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLlTWM2OD1{OD6zPUBvVQ>? MUDTRW5ITVJ?
ECC4 NXf0WWRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDXOoVKSzVyPUK4Mlc6KG6P Mm\IV2FPT0WU
OCI-AML2 NUfweWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXHPYFKSzVyPUK5MlY6KG6P MmrwV2FPT0WU
EW-3 Mnf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXUS|JKSzVyPUOwMlU6KG6P MkjyV2FPT0WU
NCI-H526 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO4[ZhUUUN3ME2zNk42PCCwTR?= MmTjV2FPT0WU
NCI-H719 NXHJepB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jyR2lEPTB;M{SuN|Ehdk1? MX7TRW5ITVJ?
KARPAS-422 M{\sV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN3LkC0JI5O MVPTRW5ITVJ?
SK-MEL-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jvSmlEPTB;M{WuNVchdk1? M3yyXXNCVkeHUh?=
ES3 NFzTbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLxcWk6UUN3ME2zOU4yQSCwTR?= NIPzRoNUSU6JRWK=
UACC-812 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Zc2lEPTB;M{WuOFQhdk1? Mk\xV2FPT0WU
C8166 Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTN3Lkegcm0> M1rRXHNCVkeHUh?=
MDA-MB-134-VI MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfWN3EzUUN3ME2zOU45PyCwTR?= NGPyepRUSU6JRWK=
D-283MED MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN5Lke5JI5O NU\EdXdXW0GQR1XS
SHP-77 NVX6dXB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrTTGFKSzVyPUO4MlA{KG6P NIfDU2dUSU6JRWK=
NCI-H2227 M4m0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOwOXFKSzVyPUSwMlQ6KG6P NFjzNpNUSU6JRWK=
SKM-1 NGXFXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfRc4pKSzVyPUSyMlY{KG6P M4j6U3NCVkeHUh?=
L-428 NXLFOoo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzvUYxKSzVyPUSzMlg3KG6P MVfTRW5ITVJ?
RPMI-6666 M4iy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H6UGlEPTB;NEWuPFkhdk1? NXPmcmpwW0GQR1XS
NCI-H716 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfQOWFKSzVyPUS4MlgyKG6P NWDr[YVOW0GQR1XS
DMS-79 NVTzVopRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD13MD63NUBvVQ>? Mn;DV2FPT0WU
RS4-11 NUW2Z|RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTVyLki4JI5O NGXlfGlUSU6JRWK=
NCI-H720 NVS4[mIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVzLkGxJI5O NXS5bpdyW0GQR1XS
MC-CAR NFLIdJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTVzLkWyJI5O NF;wTWhUSU6JRWK=
TALL-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTV|LkmxJI5O MXXTRW5ITVJ?
NCI-N87 NFrJVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfqTlVKSzVyPUW0MlE5KG6P MXrTRW5ITVJ?
P30-OHK NHjIW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTV2Lk[xJI5O Mlf3V2FPT0WU
LP-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XDOmlEPTB;NkGuNlghdk1? NVzWNIU{W0GQR1XS
YT M2nMTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTZzLkigcm0> NVjD[lhWW0GQR1XS
MRK-nu-1 M1zsT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG0[pVKSzVyPU[xMlgzKG6P NETNWIlUSU6JRWK=
BT-474 M17RcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXiy[oZWUUN3ME22OUBvVQ>? NGf2bWtUSU6JRWK=
NCI-H322M M{jJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\uV4VKSzVyPU[2MlEyKG6P NFTC[G9USU6JRWK=
NCI-H128 NXjF[mpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHtUYZYUUN3ME23OE44PyCwTR?= MkfMV2FPT0WU
KMS-12-PE NFL6N|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnleYtbUUN3ME23Ok4zPCCwTR?= NWP1flRjW0GQR1XS
KP-N-YS MoXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfQTWM2OD15Nj63OEBvVQ>? NXnuSJdVW0GQR1XS
ALL-PO NXrnOZRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLOZZNDUUN3ME23O{43PiCwTR?= NGC2Z25USU6JRWK=
EW-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL2NmdKSzVyPUe3Mlc3KG6P NXuzblk3W0GQR1XS
EW-11 NFrLN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTd6LkWyJI5O MmjYV2FPT0WU
SK-N-FI M370c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRThyLkKgcm0> NGnZTYFUSU6JRWK=
CAL-148 NVLMcHA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRThzLki0JI5O MmLSV2FPT0WU
RL NH7PRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITZ[XNKSzVyPUi2MlA6KG6P NH3WPXpUSU6JRWK=
AM-38 M3jEV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jKfGlEPTB;OEiuNFghdk1? NWjLW4lWW0GQR1XS
RH-1 M1PieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTl7Lki1JI5O NX;oWZVZW0GQR1XS
NCI-H1770 NIjuT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L2ZmlEPTB;MUCyMlQ6KG6P M3;n[XNCVkeHUh?=
SIG-M5 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELueJNKSzVyPUGwOU4xPiCwTR?= MnvEV2FPT0WU
GR-ST M{DOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fyUGlEPTB;MUGzMlM1KG6P NVPFdZJ7W0GQR1XS
ST486 NV3X[mNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fDNmlEPTB;MUG0MlA3KG6P MlfNV2FPT0WU
NCI-H1650 MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFzNT6yPUBvVQ>? NEPMPFVUSU6JRWK=
MHH-CALL-2 NVnzZpJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r3dWlEPTB;MUG1Mlchdk1? NGC2T3lUSU6JRWK=
BV-173 M{X2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PpXWlEPTB;MUKyMlcyKG6P NUTKc5U3W0GQR1XS
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u5cGlEPTB;MUS4Mlg2KG6P MYjTRW5ITVJ?
NCI-H524 NVzPTGRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfzeIJKSzVyPUG1PU4yKG6P NF\1UHhUSU6JRWK=
SCLC-21H NYrBdJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjDSI1KUUN3ME2xOVkvPDFibl2= M3fUOXNCVkeHUh?=
NCI-H1304 NVjCfmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Li[2lEPTB;MU[5MlIyKG6P NH\DSmdUSU6JRWK=
NCI-H510A NY\4Z5o{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF6NT6zO{BvVQ>? NYrJT2ozW0GQR1XS
NCI-H209 M2XuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLjdYdKSzVyPUG5Ok42OiCwTR?= M{e5dHNCVkeHUh?=
KM-H2 NWn6ZnVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULZNYJrUUN3ME2xPVcvODVibl2= M2H6T3NCVkeHUh?=
NCI-H1395 NW\IboRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJzMD6xN{BvVQ>? NGfTN5RUSU6JRWK=
NCI-H1155 M{Ht[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTJ|MD6zNkBvVQ>? MVvTRW5ITVJ?
COR-L279 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPlRmhKSzVyPUK1Nk4yPyCwTR?= NV;Rb2Y2W0GQR1XS
NCI-H1299 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJ4MT63NUBvVQ>? Ml30V2FPT0WU
EW-22 NYjvXmVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfoU4dIUUN3ME2yOlMvPzVibl2= NGjNWoNUSU6JRWK=
SK-MEL-2 NHy4e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJ6MT65JI5O MnXEV2FPT0WU
KASUMI-1 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ6Mz6wOUBvVQ>? M33obnNCVkeHUh?=
NCI-H187 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJ6Nz6wPEBvVQ>? M3jKeHNCVkeHUh?=
NCI-H2171 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETTO3BKSzVyPUK4PE46OiCwTR?= MmPyV2FPT0WU
LNCaP-Clone-FGC NY\OfIVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H5Z2lEPTB;Mkm1MlI3KG6P MWnTRW5ITVJ?
NCI-H1522 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm0OlhKSzVyPUOwO{4xPSCwTR?= M{jhdXNCVkeHUh?=
SCH MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTN{Mj6yNkBvVQ>? M2rQSXNCVkeHUh?=
THP-1 M2nq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmGxTWM2OD1|MkKuOkBvVQ>? M2H3OHNCVkeHUh?=
SNU-C1 NV\zb4loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr0dXhKSzVyPUO2Nk4xQSCwTR?= MVzTRW5ITVJ?
CA46 NYrvfWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3yTWM2OD1|N{OuOlMhdk1? MXrTRW5ITVJ?
NCI-H1963 NIXPNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2foe2lEPTB;M{i2MlE6KG6P NX3HPZp6W0GQR1XS
DEL Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ZTGNyUUN3ME2zPVEvOjdibl2= NU\rRYVSW0GQR1XS
TUR NI\IdI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojCTWM2OD1|OU[uOlEhdk1? NIjiVI5USU6JRWK=
NCI-H226 M{G1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:wd2lEPTB;NECzMlI{KG6P NH;wN41USU6JRWK=
COLO-668 M2\6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzGTWM2OD12MEOuOVchdk1? NHywZ2xUSU6JRWK=
CPC-N NIPFbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M160NWlEPTB;NECzMlc4KG6P MUXTRW5ITVJ?
NCI-H889 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf0cYNKSzVyPUS2NU46OiCwTR?= NXHhc2lYW0GQR1XS
J-RT3-T3-5 NVLB[3ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L1bmlEPTB;NUOyMlU4KG6P MUfTRW5ITVJ?
MSTO-211H NEW4UJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fVXmlEPTB;NUe0MlI3KG6P MlPrV2FPT0WU
SCC-15 NGPLenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTZ4Nz60O{BvVQ>? M3:0eXNCVkeHUh?=
SUP-T1 NGL2eWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrTIwzUUN3ME22PFYvODRibl2= NUi2PXlnW0GQR1XS
DMS-153 M{Oxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTd2Nj64N{BvVQ>? Mmf6V2FPT0WU
MS-1 NULrXVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LyWWlEPTB;N{W5MlQzKG6P M1nUN3NCVkeHUh?=
TC-YIK M1HjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;TfIM{UUN3ME23PFEvODFibl2= NWPkRmFrW0GQR1XS
RPMI-8866 NGHVe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\OfHg4UUN3ME2xNFA3NjJ6IN88US=> MnXGV2FPT0WU
KY821 NIfjPGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTFyM{[uNFQh|ryP NGrlN2lUSU6JRWK=
P31-FUJ M1Hobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK1TWM2OD1zMUGyMlc2KM7:TR?= MUjTRW5ITVJ?
COLO-824 NIPKfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTvTWM2OD1zMk[xMlc5KM7:TR?= NFL0cFJUSU6JRWK=
U-698-M MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ{NkKuNVUh|ryP M2Dm[3NCVkeHUh?=
TE-441-T NGGy[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPhO4tKSzVyPUK1NlEvPyEQvF2= NGSzZW9USU6JRWK=
IMR-5 M3nWOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTN2MEmuOlIh|ryP NGnpbJZUSU6JRWK=
NCI-H1838 NIm5fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfYTWM2OD12MUi2MlMzKM7:TR?= MlfpV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID